This website uses cookies to enhance the user experience.
L

LP-INVEST AS992 877 049

Research
Limited company
Nordre Furudalen 3 5099 BERGEN, Norge

LP-INVEST AS

Keywords

researchdevelopment workbiotechnologygenomicspharmageneticsgene samplesdna sequencingdna synthesisdna deepeninggenetic engineeringproteinsmoleculespeptide sequencinglipidglycotechniqueproteomicshormonesgrowth factorscell receptorspheromonescell culturetissue culturecrossingcell fusionvaccineimmunostimulatorsembryo manipulationprocess biotechnologybioreactorsfermentationbioprocessingbiorecoverybiodesulfurizationbiological pulp productionbiofiltrationbiological regenerationsubcellular organismsgene therapyvirusesvectors

Organization

Chairman of the board
Years since formation
16 years
since Jul 9, 2008
Type
Limited company
VAT registered
No
Number of employees
0

Ownership

Number of shares and share classes
100
1 share class
Total number of shareholders
1
person

Financials

Annual total result 2023
-680,746
NOK
Total equity 2023
2,863,145
NOK
Last update: Aug 29, 2024

Management

Management / administration

NameRoleShares
Managing Director/CEO
100 %
directly

Board

NameRoleShares
Chairman
100 %
directly
Alternate Member-

Others

NameRoleShares
B
BERGEN REGNSKAPSENTER AS
Accountant-

Top 10 individual shareholders

NameRoleShares
Managing Director/CEO, Chairman
100 %
directly
Last update: Apr 13, 2023

Ownership

Company shareholders

NameShare classNumber of sharesShare
Ordinary shares
100
100 %

Shares owned by the LP-INVEST AS

NameShare classNumber of sharesShare
B
BIOVEST AS
A-shares
10,000
33.33 %
C
CYTOVATION ASA
NO0012518952
24,052
9.92 %
P
PHOTOCURE ASA
NO0010000045
6,000
0.02 %
Last update: May 24, 2024

Financials

in NOK

Summary

Year202320222021
Total operating income
0
1,735,500
2,304,000
Annual Total Result
-680,746
47,527
-9,040
Total assets
2,870,808
3,931,464
3,906,984
Total liabilities
7,663
387,573
410,619
Total equity
2,863,145
3,543,891
3,496,365

P&L

Year202320222021
Total operating income
0
1,735,500
2,304,000
Total operating costs
24,175
1,131,629
1,268,712
Operating result
-24,175
603,871
1,035,288
Financial income/costs
-656,571
-423,880
-816,704
Profit before tax
-680,746
179,991
218,584
Total tax & extraordinary income/cost
0
132,464
227,624
Annual Total Result
-680,746
47,527
-9,040

Balance overview

Year202320222021
Total fixed assets
2,210,939
2,210,939
2,136,027
Total current assets
659,869
1,720,525
1,770,957
Total assets
2,870,808
3,931,464
3,906,984
Short term debt
0
132,465
406,095
Long term debt
7,663
255,108
4,524
Total liabilities
7,663
387,573
410,619
Contributed capital
100,000
100,000
100,000
Retained earnings
2,763,145
3,443,891
3,396,365
Total equity
2,863,145
3,543,891
3,496,365
Total equity and liabilities
2,870,808
3,931,464
3,906,984

Classification

Category
Type of organization
Limited company
Classification of institutional sector
INNL
Domestic sectors
A_IKKE-FIN
Non-financial corporations
2100
Private non-financial incorporated enterprises
Standard industrial classification
M
Main industrial area
Professional, scientific and technical activities
72
Activity
Scientific research and development
72.1
Main industrial group
Research and experimental development on natural sciences and engineering
72.11
Industrial group
Research and experimental development on biotechnology
72.110
Industrial group
Research and experimental development on biotechnology